Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,739
  • Shares Outstanding, K 48,980
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,610 K
  • EBIT $ -32 M
  • EBITDA $ -31 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.34
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings $-0.19 on 11/13/25
  • Next Earnings Date 03/26/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 333.35% (-89.59%)
  • Historical Volatility 57.67%
  • IV Percentile 56%
  • IV Rank 23.65%
  • IV High 1,204.24% on 12/02/25
  • IV Low 63.55% on 12/16/25
  • Expected Move (DTE 27) 0.0425 (6.56%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 522
  • Volume Avg (30-Day) 62
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 5,957
  • Open Int (30-Day) 5,799
  • Expected Range 0.6055 to 0.6905

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.21
  • Growth Rate Est. (year over year) +4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6400 +1.25%
on 02/20/26
1.0491 -38.23%
on 01/28/26
-0.2980 (-31.50%)
since 01/20/26
3-Month
0.6400 +1.25%
on 02/20/26
1.1500 -43.65%
on 01/09/26
-0.1081 (-14.30%)
since 11/20/25
52-Week
0.6400 +1.25%
on 02/20/26
2.2000 -70.55%
on 02/27/25
-0.7720 (-54.37%)
since 02/20/25

Most Recent Stories

More News
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.6480 (-1.49%)
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

NCI-Led Study Shows Median PFS of 9.6 Months  Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology...

PDSB : 0.6480 (-1.49%)
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

PRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.6480 (-1.49%)
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 ...

PDSB : 0.6480 (-1.49%)
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s ...

PDSB : 0.6480 (-1.49%)
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.6480 (-1.49%)
PDS Biotechnology: Q3 Earnings Snapshot

PDS Biotechnology: Q3 Earnings Snapshot

PDSB : 0.6480 (-1.49%)
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval...

PDSB : 0.6480 (-1.49%)
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering

PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.6480 (-1.49%)
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy  PDS01ADC reprograms natural killer (NK) cells to possess characteristics...

PDSB : 0.6480 (-1.49%)

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

3rd Resistance Point 0.7962
2nd Resistance Point 0.7633
1st Resistance Point 0.7057
Last Price 0.6480
1st Support Level 0.6152
2nd Support Level 0.5823
3rd Support Level 0.5247

See More

52-Week High 2.2000
Fibonacci 61.8% 1.6041
Fibonacci 50% 1.4200
Fibonacci 38.2% 1.2359
Last Price 0.6480
52-Week Low 0.6400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar